# CC-42344 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cc-42344

> CC-42344, sponsored by Cocrystal Pharma, Inc. (COCP): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CC-42344 |
| Codes | CC-42344 |
| Sponsor | Cocrystal Pharma, Inc. (COCP) https://sec-api.dev/companies/cocp/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Dec 2023: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2024-11-13, last confirmed 2026-03-31.
- Press release filed with the SEC (EX-99) (accession 0001493152-26-013837): "December 2023 we began a randomized, double-blind, placebo-controlled Phase 2a human challenge study to evaluate the safety, tolerability, and viral and clinical measurements of CC-42344 in influenza A-infected subjects in the United Kingdom, following authorization from the" https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-25-022603): "December 2023 we began a randomized, double-blind, placebo-controlled Phase 2a human challenge study to evaluate the safety, tolerability, viral and clinical measurements of CC-42344 in influenza A-infected subjects in the United Kingdom, following authorization from the" https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001641172-25-023727): "December 2023 we began a randomized, double-blind, placebo-controlled Phase 2a human challenge study to evaluate the safety, tolerability, viral and clinical measurements of CC-42344 in influenza A-infected subjects in the United Kingdom, following authorization from the" https://www.sec.gov/Archives/edgar/data/1412486/000164117225023727/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001641172-25-010537): "o In December 2023 we began a randomized, double-blind, placebo-controlled Phase 2a human challenge study to evaluate the safety, tolerability, viral and clinical measurements of CC-42344 in influenza A-infected subjects in the United Kingdom, following authorization from the UK Medicines and Healthcare Products Regulatory" https://www.sec.gov/Archives/edgar/data/1412486/000164117225010537/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001641172-25-001494): "December 2023 we began a randomized, double-blind, placebo-controlled Phase 2a human challenge study to evaluate the safety, tolerability, viral and clinical measurements of CC-42344 in influenza A-infected subjects in the United Kingdom, following authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)." https://www.sec.gov/Archives/edgar/data/1412486/000164117225001494/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-24-045083): "December 2023 we began a randomized, double-blind, placebo-controlled Phase 2a human challenge study to evaluate the safety, tolerability, viral and clinical measurements of CC-42344 in influenza A-infected subjects in the United Kingdom, following authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)." https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/ex99-1.htm

### late 2024: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0001493152-24-045083): ""In the Phase 2a influenza A challenge study with our oral PB2 inhibitor CC-42344, we expect to report topline results before year end." https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/ex99-1.htm

### Dec 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2024-12-31, last confirmed 2024-12-31.
- Press release filed with the SEC (EX-99) (accession 0001493152-24-052600): "The Company initiated the Phase 2a human challenge study in December 2024 following authorization from the MHRA." https://www.sec.gov/Archives/edgar/data/1412486/000149315224052600/ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cc-42344.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CC-42344 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cc-42344

```bibtex
@misc{secapidev_pdufa_cc_42344_20261116,
  title        = {CC-42344 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cc-42344}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cc_42344_20261116","title":"CC-42344 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cc-42344","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
